These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

761 related items for PubMed ID: 27817164

  • 21. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
    Arcieri R, Germinario EA, Bonati M, Masi G, Zuddas A, Vella S, Chiarotti F, Panei P, Italian Attention-Deficit/Hyperactivity Disorder Regional Reference Centers.
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):423-431. PubMed ID: 23362511
    [Abstract] [Full Text] [Related]

  • 22. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.
    van den Ban E, Souverein P, Swaab H, van Engeland H, Heerdink R, Egberts T.
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):55-61. PubMed ID: 20166797
    [Abstract] [Full Text] [Related]

  • 23. Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands.
    van den Ban E, Souverein PC, Swaab H, van Engeland H, Egberts TC, Heerdink ER.
    Atten Defic Hyperact Disord; 2010 Dec; 2(4):213-20. PubMed ID: 21258431
    [Abstract] [Full Text] [Related]

  • 24. Effectiveness of atomoxetine and methylphenidate for problematic online gaming in adolescents with attention deficit hyperactivity disorder.
    Park JH, Lee YS, Sohn JH, Han DH.
    Hum Psychopharmacol; 2016 Nov; 31(6):427-432. PubMed ID: 27859666
    [Abstract] [Full Text] [Related]

  • 25. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
    Hodgkins P, Sasané R, Christensen L, Harley C, Liu F.
    Curr Med Res Opin; 2011 Nov; 27 Suppl 2():53-62. PubMed ID: 21973231
    [Abstract] [Full Text] [Related]

  • 26. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
    Marcus SC, Wan GJ, Kemner JE, Olfson M.
    Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
    [Abstract] [Full Text] [Related]

  • 27. Prescribing patterns for attention deficit hyperactivity disorder among children and adolescents in Taiwan from 2004 to 2017.
    Liao HC, Lin FJ, Hsu CN, Gau SS, Wang CC.
    J Formos Med Assoc; 2023 Jun; 122(6):514-517. PubMed ID: 36931958
    [Abstract] [Full Text] [Related]

  • 28. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
    Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.
    Appl Health Econ Health Policy; 2012 Nov 01; 10(6):381-95. PubMed ID: 23113551
    [Abstract] [Full Text] [Related]

  • 29. Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany.
    Braun S, Russo L, Zeidler J, Linder R, Hodgkins P.
    Clin Ther; 2013 May 01; 35(5):673-85. PubMed ID: 23587606
    [Abstract] [Full Text] [Related]

  • 30. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun 01; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 31. Switch to Lisdexamfetamine in the Treatment of Attention-Deficit Disorder at a Psychiatric Outpatient Clinic for School-Aged Children: A Danish Cohort Study.
    Søndergaard NR, Nørøxe KB, Carlsen AH, Randing SH, Warrer P, Thomsen PH, Clausen L.
    J Child Adolesc Psychopharmacol; 2024 Apr 01; 34(3):137-147. PubMed ID: 38608011
    [Abstract] [Full Text] [Related]

  • 32. Shared and Unique Effects of Long-Term Administration of Methylphenidate and Atomoxetine on Degree Centrality in Medication-Naïve Children With Attention-Deficit/Hyperactive Disorder.
    Fu Z, Yuan J, Pei X, Zhang K, Xu C, Hu N, Xie R, Zhao Y, Wang Y, Yang L, Cao Q.
    Int J Neuropsychopharmacol; 2022 Sep 28; 25(9):709-719. PubMed ID: 35524732
    [Abstract] [Full Text] [Related]

  • 33. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
    Fuentes J, Danckaerts M, Cardo E, Puvanendran K, Berquin P, De Bruyckere K, Montoya A, Quail D, Escobar R.
    J Clin Psychopharmacol; 2013 Dec 28; 33(6):766-74. PubMed ID: 23963057
    [Abstract] [Full Text] [Related]

  • 34. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.
    Bédard AC, Stein MA, Halperin JM, Krone B, Rajwan E, Newcorn JH.
    J Child Psychol Psychiatry; 2015 Jan 28; 56(1):40-8. PubMed ID: 24942409
    [Abstract] [Full Text] [Related]

  • 35. Impact of negative media publicity on attention-deficit/hyperactivity disorder medication in Taiwan.
    Wang LJ, Lee SY, Yuan SS, Yang CJ, Yang KC, Lee TL, Shyu YC.
    Pharmacoepidemiol Drug Saf; 2016 Jan 28; 25(1):45-53. PubMed ID: 26549311
    [Abstract] [Full Text] [Related]

  • 36. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
    Yang L, Cao Q, Shuai L, Li H, Chan RC, Wang Y.
    Int J Neuropsychopharmacol; 2012 Feb 28; 15(1):15-26. PubMed ID: 22017969
    [Abstract] [Full Text] [Related]

  • 37. Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
    Bhang SY, Hwang JW, Kwak YS, Joung YS, Lee S, Kim B, Sohn SH, Chung US, Yang J, Hong M, Bahn GH, Choi HY, Oh IH, Lee YJ.
    J Korean Med Sci; 2016 Aug 28; 31(8):1284-91. PubMed ID: 27478341
    [Abstract] [Full Text] [Related]

  • 38. Differential Treatment Effects of Methylphenidate and Atomoxetine on Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder.
    Wu CS, Shang CY, Lin HY, Gau SS.
    J Child Adolesc Psychopharmacol; 2021 Apr 28; 31(3):187-196. PubMed ID: 33890819
    [Abstract] [Full Text] [Related]

  • 39. ADHD Medication Trends in Turkey: 2009-2013.
    Öner Ö, Yilmaz EŞ, Karadağ H, Vural M, Vural EH, Akbulat A, Gürsöz H, Türkçapar H, Kerman S.
    J Atten Disord; 2017 Dec 28; 21(14):1192-1197. PubMed ID: 24554298
    [Abstract] [Full Text] [Related]

  • 40. Cost of ADHD treatment using methylphenidate and atomoxetine in the South African private healthcare sector.
    Munasur-Naidoo AP, Truter I.
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec 28; 19(6):677-684. PubMed ID: 31456453
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.